Changes in prostate‐specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men

Background The objective of this study was to determine the effect of Medicaid expansion under the Patient Protection and Affordable Care Act (January 1, 2014) on the epidemiology of high‐risk prostate‐specific antigen (PSA) levels (≥20 ng/mL) at the time of prostate cancer (PCa) diagnosis. The authors hypothesized that better access to care would result in a reduction of high‐risk features at diagnosis. Methods A retrospective cohort study was performed of 122,324 men aged